Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Hadassah Medical Organization Jerusalem Institute for Child Development |
---|---|
Information provided by: | Hadassah Medical Organization |
ClinicalTrials.gov Identifier: | NCT00318162 |
This study will examine the effects of low-dose naltrexone (LDN) on children with autistic spectrum disorders. The investigators hope to show a positive effect on social functioning and language.
Condition | Intervention | Phase |
---|---|---|
Pervasive Developmental Disorder |
Drug: low dose naltrexone |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | Randomized Double-Blind Trial of Low-Dose Naltrexone for Children With PDD |
Estimated Enrollment: | 50 |
Fifty children aged three to six years will be recruited for the study. They will be randomly assigned to receive either LDN or placebo for two months after which the treatment groups will be switched over. Assessments of functioning will be obtained from a video-taped play session, and by parent and teacher questionnaires at baseline, after two months and after four months.
Ages Eligible for Study: | 3 Years to 6 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Contact: David S Wilensky, MD | 97227828142 | davidvil@012.net.il |
Israel | |
Jerusalem Institute for Child Development | |
Jerusalem, Israel |
Principal Investigator: | David S Wilensky, MD | Jerusalem Institute for Child Development |
Study ID Numbers: | PDDLDN-HMO-CTIL |
Study First Received: | April 25, 2006 |
Last Updated: | May 2, 2006 |
ClinicalTrials.gov Identifier: | NCT00318162 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
autism PDD LDN naltrexone |
Child Development Disorders, Pervasive Developmental Disabilities Mental Disorders |
Autistic Disorder Naltrexone Mental Disorders Diagnosed in Childhood |
Pathologic Processes Disease Sensory System Agents Therapeutic Uses Physiological Effects of Drugs |
Narcotic Antagonists Peripheral Nervous System Agents Central Nervous System Agents Pharmacologic Actions |